BerriQi for Kids: Boysenberry and apple product for respiratory recovery in kids

Not Applicable

Recruiting

• Conditions: Respiratory; Upper respiratory tract infection; Respiratory - Other respiratory disorders / diseases; Infection - Other infectious diseases; Alternative and Complementary Medicine - Other alternative and complementary medicine

• Registration Number: ACTRN12624000398505
• Lead Sponsor: Anagenix

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-04-03
• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 62

Inclusion Criteria

Participants and their family are willing and able to give informed consent for participation in the trial.
5-13 years of age.
Willing to comply with the study protocol .
Have upper respiratory infection symptoms triggering a school absence.

Exclusion Criteria

Allergic to berries
Not willing to provide informed consent

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To assess if ingestion of two BerriQi chewable tablets (500 mg each) for 14 days compared to placebo can improve quality of life as determined by global illness severity domain from WURSS-K questionnaires[Wisconsin Upper Respiratory Symptoms Survey-for Kids (WURSS-K) Baseline (the first day of school in which a child is absent due to respiratory symptoms, prior to beginning BerriQi treatment), Day 7 (7 days after the first school absence due to respiratory illness; primary outcome). Day 14 (14 days after the first school absence due to respiratory illness).]